Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Harold Engstrom who wrote (7812)	1/28/2003 9:33:22 AM
From: Biomaven	Read Replies (1) \| Respond to of 52153

Harold, For a potential blockbuster drug for a chronic condition, the FDA would want to see big numbers of patients in fairly lengthy trials. ALT would also need to partner up before running Ph III trials, and this in turn needs to wait for the PH II results. So my guess is that 4 years isn't that far off. They might get priority review, which could cut six months off the timetable. Peter P.S. Tough day yesterday in biotech land - we had held up much better than the rest of the market in the recent decline, but yesterday we partially made up for it.